Top Page
Optima Health PLC
(LSE:OPT)
Optima Health PLC (OPT) vs. iShares MSCI United Kingdom ETF (EWC)
Optima Health PLC Business Overview & Revenue Model
Optima Health PLC Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 113.75M | 105.05M | 110.89M | 115.35M | 22.39M |
| Gross Profit | 24.41M | 33.04M | 36.47M | 36.94M | 8.04M |
| EBITDA | 16.42M | 13.65M | 10.06M | 11.06M | 1.74M |
| Net Income | 3.53M | 1.65M | -1.08M | 1.59M | -246.00K |
Balance Sheet | |||||
| Total Assets | 221.43M | 218.14M | 210.39M | 225.27M | 192.56M |
| Cash, Cash Equivalents and Short-Term Investments | 8.27M | 14.80M | 8.22M | 12.73M | 6.90M |
| Total Debt | 19.40M | 21.68M | 12.45M | 57.87M | 34.06M |
| Total Liabilities | 51.97M | 50.02M | 48.11M | 97.24M | 66.25M |
| Stockholders Equity | 169.45M | 168.12M | 0.00 | 128.03M | 126.31M |
Cash Flow | |||||
| Free Cash Flow | 7.93M | -1.06M | 10.00M | 2.40M | -1.63M |
| Operating Cash Flow | 9.76M | 2.69M | 12.85M | 6.59M | -836.00K |
| Investing Cash Flow | -11.76M | -5.65M | -2.85M | 843.00K | 7.77M |
| Financing Cash Flow | 880.00K | -3.33M | -1.63M | -1.61M | -205.00K |
Optima Health PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £220.41B | 30.61 | 22.34% | 1.53% | 10.20% | 40.57% | |
68 Neutral | £286.68M | 54.44 | 6.70% | 3.40% | 17.95% | -54.68% | |
55 Neutral | £700.13M | 37.83 | 2.51% | 1.37% | 6.95% | -34.38% | |
53 Neutral | £177.55M | 50.38 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Optima Health PLC Corporate Events
Optima Health PLC reported a 17% increase in revenue to £59.5 million for the six months ending September 2025, driven by strategic acquisitions and new contract wins. The company completed the acquisition of Cognate Health in Ireland and Care first’s Employee Assistance Business, enhancing its service offerings and geographic reach. Despite a slight decrease in adjusted EBITDA, Optima Health has a strong business pipeline and is undergoing a transformation program to improve margins and operational efficiency. The company is well-positioned to capitalize on market opportunities, with plans to grow revenue to £200 million and adjusted EBITDA to £40 million in the medium term.
The most recent analyst rating on (GB:OPT) stock is a Buy with a £225.00 price target. To see the full list of analyst forecasts on Optima Health PLC stock, see the GB:OPT Stock Forecast page.
Optima Health PLC has announced that it will release its Half Year Results for the period ending 30 September 2025 on 10 December 2025. The announcement will be accompanied by an in-person briefing for analysts, hosted by CEO Jonathan Thomas and CFO Heidi Giles, with additional access via a live webcast and conference call. This upcoming release is significant for stakeholders as it will provide insights into the company’s financial performance and strategic positioning in the health and wellbeing sector.
The most recent analyst rating on (GB:OPT) stock is a Buy with a £225.00 price target. To see the full list of analyst forecasts on Optima Health PLC stock, see the GB:OPT Stock Forecast page.
Optima Health PLC reported a 17% revenue growth for the half year ending September 2025, reaching approximately £59 million, aligning with market expectations. The company has made strategic acquisitions, including Cognate Health in Ireland and Care first Employee Assistance Business, to enhance its market share and capabilities. These moves mark Optima’s entry into international markets and strengthen its UK presence. The company is also investing in technology to improve its platform, aiming to drive organic growth and improve margins. Optima’s ongoing £210 million contract with the UK Armed Forces and a strong pipeline of new opportunities further solidify its position as a leading occupational health provider.
The most recent analyst rating on (GB:OPT) stock is a Buy with a £225.00 price target. To see the full list of analyst forecasts on Optima Health PLC stock, see the GB:OPT Stock Forecast page.
Optima Health PLC has reported a 17% revenue growth for the first half of 2025, reaching approximately £59 million, aligning with market expectations. The company has made strategic acquisitions, including Cognate Health in Ireland and Care first Employee Assistance Business, to expand its market reach and capabilities. These moves are part of Optima’s strategy to enhance its platform and improve margins, positioning itself for further growth in the UK and internationally. The company’s robust financial position and ongoing investments in technology are expected to drive organic growth and reinforce its market leadership in occupational health and wellbeing solutions.
The most recent analyst rating on (GB:OPT) stock is a Buy with a £225.00 price target. To see the full list of analyst forecasts on Optima Health PLC stock, see the GB:OPT Stock Forecast page.